Introduction
Treatment response in patients with major depressive disorder (MDD) is only partially predicted by clinical symptom profiles, and depressive symptoms alone fail to account for the majority of biological heterogeneity in treatment response (Carragher, Adamson, Bunting, & McCann, 2009; Cassano et al., 2009; Charney & Drevets, 2002; Harald & Gordon, 2012) . Recent efforts to better parse this heterogeneity have included molecular, physiological, imaging, and neuropsychological measures combined with clinical data, with the aim of facilitating more personalized patient care (A. John Rush & Hicham M. Ibrahim, 2018; Rush & Ibrahim, 2018) .
To support biomarker identification in MDD, we recently proposed three depressive phenotypes based on items from the 17-item Hamilton Rating Scale for Depression (HRSD 17 ) (Ahmed et al., 2018 ) that may reflect distinct neural processes aligned with the Research Domain Criteria (RDoC) proposed by the National Institute of Mental Health (Insel et al., 2010) . These phenotypes, with corresponding question numbers on the HRSD 17 , were categorized as: 1) core depressive (CD+: depressed mood #1, work and activities #7); 2) neurovegetative symptoms of melancholia (NVSM+: late insomnia #6, somatic symptoms gastrointestinal #12); and 3) anxious features (ANX+: agitation #9, psychological anxiety #10, somatic anxiety #11, and hypochondriasis #15).
The present study was undertaken to determine whether levels of acylcarnitines at baseline and after eight weeks of treatment with a selective serotonin reuptake inhibitor (SSRI), or changes in the acylcarnitine profiles from baseline to week eight would discriminate these phenotypes from the others. This report focuses on acylcarnitines due to their emerging role in the central nervous system and relevance to MDD (Chen et al., 2014) . Acylcarnitines are involved in mitochondrial function and energy metabolism, anti-oxidative functions and membrane stability, gene expression, neurotransmission, and neuroprotection (Calabrese, Stella, Calvani, & Butterfield, 2006; Nałęcz, Miecz, Berezowski, & Cecchelli, 2004; Pettegrew, Levine, & McClure, 2000; Virmani & Binienda, 2004; ZANELLI, SOLENSKI, ROSENTHAL, & FISKUM, 2005) . Carnitine is present in the brain (Bresolin, Freddo, Vergani, & Angelini, 1982; Shug, Schmidt, Golden, & Fariello, 1982) , where it transfers acetyl groups formed during β -oxidation to the cytosol, and it assists with the transfer of fatty acids from cytosol to mitochondria for energy production (FRITZ & MCEWEN, 1959; Jones, McDonald, & Borum, 2010) .
Elevated medium-and long-chain acylcarnitine concentrations in blood have been associated with incomplete β -oxidation of fatty acids in a rat model of depression (Chen et al., 2014) . In clinical studies, patients with a lifetime diagnosis of MDD demonstrated altered mitochondrial function or reduced ATP production (Beasley et al., 2006; Gardner et al., 2003; Suomalainen et al., 1992) . Further, patients with mitochondrial disorders frequently have depressive symptoms or a history of MDD (Fattal, Link, Quinn, Cohen, & Franco, 2007; Kato, 2001; Manji et al., 2012) . Acetyl-L-carnitine levels appear to be lower in treatment-resistent MDD patients (n=71) compared to healthy controls (n=45) (Nasca et al., 2018) . Moreover, patients undergoing hemodialysis who were administered L-carnitine had increased total, free, and acylcarnitine levels in plasma and an associated decrease in depression rating scales scores (Tashiro et al., 2017) . To date, we are unaware of any studies that link acylcarnitine levels or their changes under antidepressant treatment with clinical phenotypes in patients with major depression.
This study addresses the following questions: 
Materials and Methods

Study Design and Participants
The sample comprised 240 MDD participants from the Mayo Clinic NIHPharmacogenomics Research Network -Antidepressant Medication Pharmacogenomics Study (PGRN-AMPS) (Mrazek et al., 2014) . Participant selection, symptomatic evaluation, and blood sample collection for the PGRN-AMPS clinical trial have been described in our previous work (Gupta et al., 2016; Ji et al., 2014; Mrazek et al., 2014; Schiepers, Wichers, & Maes, 2005) .
MDD symptoms were assessed using the HRSD 17 at baseline and after eight weeks of treatment with citalopram or escitalopram. Blood samples for metabolomics were collected at these same time points. The data extraction protocol followed the STROBE guidelines (von Elm, Altman, Egger, & et al., 2007) .
The study was approved and monitored by the Institutional Review Boards of Mayo Clinic and conformed to the standards of the Declaration of Helsinki. All participants provided written informed consent prior to participation in this study.
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We previously defined three clinical phenotypes that aligned with RDoC conceptual models (Insel et al., 2010) 
Results
Participant Characteristics
Plasma metabolite data were available from 240 MDD participants. At baseline, age, gender, and baseline HRSD 17 scores did not significantly differ across the three groups. The demographic and clinical characteristics of the study sample are detailed in Table 1 .
At baseline, acylcarnitine metabolomic patterns that differentiate each pure phenotype (CD+; NVSM+; ANX+) from the others.
CD+ participants demonstrated significantly lower levels of C0, C3, C5:1, C5-DC/C6-OH, C16-OH, and C18 acylcarnitines compared to ANX+ participants. Moreover, C5-DC/C6-OH and C16-OH acylcarnitines levels were significantly lower, and C10 significantly higher, in the NVSM+ participants compared to the ANX+ participants. Figure 2 shows the baseline and week eight acylcarnitine metabolite concentrations for each of the three phenotypes.
Supplemental Table 3 shows the baseline and week eight differences between each phenotype and significant p-values.
At eight weeks, acylcarnitine metabolomic patterns that differentiate each pure phenotype (CD+; NVSM+; ANX+) from the others.
At eight weeks, CD+ participants had significantly higher levels of C5-DC/C6-OH, C5-M-DC, C6, C14:1, C16, C16-OH, C16:1, and C18:1-OH acylcarnitines compared to NVSM+ participants. CD+ participants had significantly lower levels of C2, C3 and C6 acylcarnitines compared to ANX+ participants. NVSM+ participants had significantly lower levels of C0, C2, C3, C5-DC/C6-OH, C5-M-DC, C6, C10, C14:1, C16, C16-OH, C16:1 and C18:1-OH acylcarnitines compared to ANX+ participants. (Figure 2 , Supplemental Table 3 ).
3. Baseline to week eight changes in acylcarnitine metabolomic patterns that differentiate each pure phenotype (CD+; NVSM+; ANX+) from the others.
Several short-, medium-, and long-chain acylcarnitines significantly changed in each of the three phenotypes over the eight-week course of SSRI treatment. The heatmap in Figure 3 illustrates key changes in acylcarnitine evaluated after eight weeks of treatment. Only CD+ participants had significantly increased levels of five short-chain and one long-chain acylcarnitines. Moreover, NVSM+ participants had significantly decreased levels of C2, C6 and six long-chain acylcarnitines (C14:1, C14:2, C16, C18, C18:1, C18:1-OH and C18:2); C5 was significantly increased only in ANX+ participants. C8, C10, and C12 levels significantly decreased in both CD+ and NVSM+ participants, and C0, C3, and C4 levels significantly increased in both CD+ and ANX+ participants. Worth noting, all three phenotypes showed significant decreases in C5-OH, C16:1, C18:1 and C18:2 acylcarnitine levels. Significant pvalues ranged from <0.05 to <0.001. Figure 3 and Supplemental Table 4 show change of metabolite levels from baseline to eight weeks of SSRI treatment among the three phenotypes and significant p-values (rows represent the acylcarnitine and columns represent the phenotype).
Discussion
This study assessed whether three symptomatically defined phenotypes of MDD could be differentiated based on acylcarnitine profiles at baseline, after eight weeks of citalopram/escitalopram treatment, and temporal changes in the 23 acylcarnitines from baseline to eight weeks of treatment. Both the cross-sectional levels and the changes in acylcarnitine levels distinguished the three pure phenotypes. In the temporal analyses, eight weeks of SSRI treatment was associated with significant increases in short-chain acylcarnitines in the CD+ and ANX+ phenotypes, whereas in the NVSM+ phenotype the treatment was associated with significant decreases in medium-and long-chain acylcarnitines.
After eight weeks of SSRI treatment, acylcarnitine levels in NVSM+ participants were significantly lower than in ANX+ participants. The NVSM+ group showed a decrease in the levels of C2 acylcarnitines after eight weeks of citalopram/escitalopram. The NVSM+ phenotype was defined by loss of sleep and appetite. In a prior study, C2 levels were lower in treatment-resistant depressed patients (n=71) compared to healthy controls (n=45) (Nasca et al., 2018) . Another study found a decrease in C2 concentrations after ketamine treatment (n=29) compared to placebo (n=29) (Moaddel et al., 2018) . Moreover, increased levels of C2 have been associated with fasting state (Costa, De Almeida, Jakobs, Poll-The, & Duran, 1999; Frohlich, Seccombe, Hahn, Dodek, & Hynie, 1978; Hoppel & Genuth, 1980) . Of interest, people with narcolepsy, which is characterized by abnormal sleep, may have low levels of C2 and increased levels of carnitine palmitoyltransferase 1B, which suggests dysfunction in the fatty acid β -oxidation pathway (Miyagawa et al., 2011) . Davies and colleagues found increases in this C2 in sleep deprivation (Davies et al., 2014) and they concluded that any changes in the acylcarnitines involved in fatty acid β -oxidation are implicated in sleep regulation (Davies et al., 2014) , which is a key component of the NVSM+ phenotype. Our results also show that the NVSM+ and CD+ phenotypes were associated with decreased levels of C8, C10 and C12 after eight weeks of treatment. Furthermore, the changes from baseline to eight weeks included decreases in several medium-and long-chain acylcarnitines in both the NVSM+ and CD+ phenotypes.
The ANX+ phenotype had significantly higher levels of acylcarnitines at baseline and after treatment compared to the CD+ and NVSM+ phenotypes. Short-and long-chain acylcarnitine levels were also significantly different between the CD+ and ANX+ phenotypes.
After eight weeks of treatment, short-chain acylcarnitine levels were significantly lower in the CD+ phenotype compared to the ANX+ phenotype. Despite these different symptom profiles, the metabolomic profiles of the CD+ and ANX+ phenotypes overlapped. C0, C3 and C4 levels significantly increased in both phenotypes, although C5 was only increased in the ANX+ phenotype. The CD+ phenotype is defined by patients who are sad and anhedonic, and the ANX+ phenotype is defined by patients who have symptoms of psychological and somatic anxiety and agitation. C0 levels are inversely correlated with self-rated depressive symptoms (Fukami et al., 2014) . Tashiro and colleagues have suggested that C4 levels are associated with depressive symptoms (Tashiro et al., 2017) . Moreover, hemodialysis patients had a decrease in their self-rated depression scale associated with increased acylcarnitine levels of C4 and C5.
To summarize, the current data demonstrated that three clinically-defined depression phenotypes have distinct patterns of acylcarnitine levels at baseline and after eight weeks of antidepressant treatment. Also, these phenotypes were uniquely and distinctly related to changes in acylcarnitine levels induced by SSRI exposure. These findings and the relationship of acylcarnitine levels with mitochondrial fatty acid β -oxidation and branched-chain amino acid 1 8
MDD. Further, these findings may reflect changes in mitochondrial function or ATP production in patients with MDD. Linking acylcarnitine metabolomic data to genetic data has proven to be a powerful approach for highlighting variation in predicting antidepressant response among depressed individuals (Ji et al., 2011; Neavin, Kaddurah-Daouk, & Weinshilboum, 2016) . These findings may help to develop a metabolomic profile or 'metabotype' of MDD patients, as
indexed by an electrochemistry metabolomics platform total output (digital map), with the aim of improving subtype classification of the MDD syndrome.
Limitations
The study has several limitations. Analyses were performed on a subset of MDD participants, thereby limiting the generalizability of the findings. Some of the reported acylcarnitines, especially dicarboxylic and hydroxylated species (C3DC, C5DC, C5MDC, C16OH, C18OH)-are canonically elevated only in patients with rare inborn errors of metabolism (see Supplemental Table 2 ), and are of very low concentrations in most individuals.
The flow-injection MS/MS method used in this study may lack molecular specificity to confirm exact structure for low-level species, even though the measures reported herein show excellent technical reproducibility. Importantly, although we reported many acylcarnitines which are represent other metabolic disorders in those individuals. Our study lacked inclusion of a healthy control group with which to compare and contrast the acylcarnitine profiles of the MDD phenotypes, and allow examination of whether these metabolite changes are due to the drug effect or are unique to the phenotype.
Conclusions
Baseline and week eight acylcarnitine concentrations, evaluated both cross-sectionally and by temporal change, indicated unique acylcarnitine signatures that distinguish clinicallydefined MDD phenotypes from each other. This study supports the possibility of using acylcarnitines as a tool for understanding personal variation in MDD drug response; this moght allow for sub-classifications of MDD to CD+, NVSM+ and ANX+ patients and the linking of acylcarnitine changes to mitochondrial fatty acid β -oxidation and branched-chain amino acid catabolism. . 
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